JW Theriac

WRS (Tryptophanyl tRNA synthetase)

• Novel biomarker for sepsis diagnosis
• WRS is involved in innate immune response and is rapidly released into the blood during infection
• Secreted level of WRS was increased in patients with sepsis caused by various types of infection (bacteria, fungi, viruses). WRS as a potential biomarker for sepsis diagnosis has been identified.
• Will be approved by MFDS(Ministry of Food and Drug Safety) in 2020
• Secreted tryptophanyl-tRNA synthetase as a primary defense system against infection (Ahn YH et al, Nature microbiology, 2016)

POCT (Point of care testing)

• Rapid diagnostic platform for measuring biomarkers in blood
• Automated analyzer based on CLEIA.
• Up to 6 tests per run in less than 20 minutes
• will be released in 2020

CFB (Complement factor B)

• Novel biomarker for early diagnosis of pancreatic cancer
• CFB is involved in the development and metastasis of pancreatic cancer and can be detected in the blood from the early stage of cancer. 
• When combined with the existing pancreatic cancer biomarker CA19-9, CFB improves diagnostic accuracy of pancreatic cancer.
• Underdeveloping CFB and CA19-9 multi-biomarker measurement kits and analysis algorithms. 
• Identification of Human Complement Factor B as a Novel Biomarker Candidate for Pancreatic Ductal Adenocarcinoma (Lee et al, Journal of Proteome research, 2014)

POCT (Point of care testing)

• Original technology patent registration (10-1594287)
• Patent application status
  • US patent registered (15/347812)
  • Japanese patent registered (2016-567615)
  • European patent registered (14 892 029.1)
  • Chinese patent registered (201480078913.3)
  ​